Domicell - Stem Cell Cardiac Treatment

Company Summary

Domicell’s Stem Cell Implantable Bioreactor (SCIB) is a novel cell delivery platform designed to overcome the limitations of current stem cell therapy for the heart. While conceived to prevent heart failure, SCIB-based cell therapy can be readily adapted to deliver a variety of cell products to treat other conditions, both cardiac and non-cardiac.​

Year Founded:  2018

Key Executives:
• Monica Tanase-Coles, CEO & Co-Founder
• Chao-Wei Hwang, Co-Founder & CSO

Location:  Baltimore, MD

Company Status:  Private

Year Invested:  2018

Investment Status:  Current

Board Member:
Alex Andrianopoulos